Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind, study of the Gardos channel blocker senicapoc (CA-17043)
Ataga KI, Reid M, Et al. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind, study of the Gardos channel blocker senicapoc (CA-17043). Br J Haematol. 2011; 153:92-104.